Your best medicine news resource
May 15th 2008Drug InformationCervical Cancer
33,000 women in Latin America and the Caribbean die each year of preventable cervical cancer, caused by a virus that infects 20 percent of men and women in the region and as many as 30 percent of the youngest women, according to a new study.
More: continued here
May 15th 2008Drug InformationCervical Cancer
Women who do not undergo regular cervical cancer screening tests are more likely to be diagnosed with the disease than those who do, according to an audit of the Swedish national cervical cancer screening program published online April 29 in the Journal of the National Cancer Institute. Participation in screening reduces the risk for all types of cervical cancers in all ages.
More: continued here
May 15th 2008Drug InformationCervical Cancer
Starpharma Holdings Ltd (ASX:SPL, OTCQX:SPHRY) announced that recent studies have shown that SPL7013, the active ingredient in its topical microbicide VivaGel(R), inhibits clinically-relevant strains of the human papillomavirus (HPV) in laboratory tests. Starpharma CEO, Dr Jackie Fairley said: “These are exciting results which have positive implications for VivaGel(R), and which merit further investigation.
More: continued here
May 15th 2008Drug InformationCervical Cancer
Because the first national study of its kind has found that U.S. mothers report they are less likely to vaccinate daughters under age 13 against human papillomavirus virus (HPV), even though the vaccine is recommended for girls at age 11 and 12, it’s incumbent upon the healthcare community to work to improve moms’ acceptance of the vaccination for younger daughters, say researchers at Cincinnati Children’s Hospital Medical Center who conducted the study.
More: continued here
May 15th 2008Drug InformationCervical Cancer
Certain strains of human papillomavirus (HPV) are sexually transmitted and can cause cervical cancer and genital warts. In 2006, the U.S. Food and Drug Administration approved Gardasil, a prophylactic HPV vaccine marketed by Merck. It is recommended for girls and women 9 to 26 years old, but in almost all states, it is not mandated.
More: continued here
May 15th 2008Drug InformationCervical Cancer
Third Wave Technologies Inc. (NASDAQ: TWTI) announced that the company has submitted the pre-market approval (PMA) applications for its two human papillomavirus, or HPV, testing products to the U.S. Food and Drug Administration. “The submission of Third Wave’s two HPV PMA applications marks the completion of a monumental undertaking by the entire Third Wave team,” said Kevin T. Conroy, president and chief executive of Third Wave.
More: continued here
May 15th 2008Drug InformationCervical Cancer
The results of a year long clinical trial examining the effects of mushroom supplementation in patients with Human Papillomavirus (HPV) have recently been presented at congress. Dr. Jose Silva Couto and Dr. Daniel Pereira da Silva of the Cervical Pathology Unit of the Portuguese Institute of Oncology in Coimbra, Portugal presented their findings at the 20th European Congress of Obstetrics and Gynaecology, in Lisbon Portugal.
More: continued here
May 15th 2008Drug InformationCervical Cancer
Although CDC recommends that girls receive the human papillomavirus vaccine at age 11 or 12 to protect against cervical cancer before the onset of sexual activity, mothers of girls under age 13 are less willing to have their daughters vaccinated than mothers of older girls, a new study has found, the
More: continued here
May 15th 2008Drug InformationCervical Cancer
Thirty-three thousand women in Latin America and the Caribbean die each year of preventable cervical cancer, caused by a virus that infects 20 percent of men and women in the region and as many as 30 percent of the youngest women, according to a new study.
More: continued here
May 15th 2008Drug InformationCervical Cancer
Health Discovery Corporation (OTCBB: HDVY), a leader in support vector machine (SVM) based molecular diagnostics development, and DCL Medical Laboratories LLC, Indianapolis, IN, a full-service clinical reference laboratory focused on women’s health, today announced the signing of a Letter of Intent for the companies to jointly develop an SVM-based computer assisted diagnostic (CAD) test for the analysis of cervical cells.
More: continued here
Your best medicine news resource
